Table 2. Summary of economic findings.

Biological	Cost per PASI 75a	References	Cost per DLQI MIDa	References	Cost per QALYa	Referen-ces
Adalimumab	7,325–92,871	[28, 29, 32, 34, 36, 40, 48–50, 52, 53, 56, 58, 63, 64, 67–70, 72, 75, 76, 79]	3,655–26,871	[28, 64, 75]	39,952–48,341	[55, 73, 74]
Alefacept	36,430–200,734	[28, 42, 49, 50, 61, 63, 64, 66, 67, 75, 80]	28,167–155,255	[28, 63, 64, 75]	NR	NA
Apremilastb	47,960–157,309	[31, 32]	NR	NA	NR	NA
Efalizumab	15,524–78,937	[34, 49, 50, 61, 63, 64, 66, 67]	5,478–6,831	[63, 64]	59,009	[73]
Etanercept	11,590–138,009	[28, 29, 32, 34, 36, 37, 40, 42, 48–51, 56, 58, 60, 61, 63, 64, 66–70, 72, 75, 76, 79, 80]	2,342–44,796	[28, 63, 64, 75]	6,347–59,069	[37, 51, 55, 59, 73, 74]
Infliximab	8,077–229,392	[28, 29, 32, 34, 36, 40, 42, 48–50, 52, 53, 56, 58, 63, 64, 66–70, 72, 75, 76]	3,652–11,348	[28, 63, 64, 75]	62,767–73,021	[73, 74]
Ixekizumab	62,707	[32]
Ustekinumab	10,151–136,075	[28, 29, 32, 36, 38, 40, 48, 52, 53, 56, 58, 60, 67–70, 72, 75, 76, 79]	15,500–32,144	[28, 75]	NR	NA
Secukinumab	10,654–113,858	[32, 38, 53]	NR	NA	56,380–72,544	[39, 57]

^a Cost per outcome in USD is presented as compared to non-biologic therapy or placebo. Incremental analyses results comparing two biologicals are not included in this table. In addition, studies evaluating treatment sequences are not considered.

^b Apremilast was compared to methotrexate.

DLQI MID: minimal important difference in the Dermatology Life Quality Index; NA: not assessed; NR: not reported; PASI 75: reduction of the Psoriasis Area and Severity Index by 75%; QALY: Quality-Adjusted Life Year.